Evidence map›Paper›PMID 42379761›Full record

ArticleIn vivo (Athens, Greece)

Olanzapine Use and Vomiting Incidence in Chemotherapy-receiving Patients With Cervical Cancer: Multicenter Post Hoc Analysis.

Yusuke Kawamura, Kensuke Yoshida, Hajime Morita, Masaki Nakai, Takuma Matsumoto, Yoshinobu Gohara, Naoto Hoshino, Naoya Tonomura, Manami Banba, Ayako Yamaguchi and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yusuke KawamuraDivision of Hospital Pharmacy, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; y.kawa@city-hosp.naka.hiroshima.jp.
Kensuke YoshidaDepartment of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.
Hajime MoritaDivision of Pharmacy, St. Marianna University Hospital, Kawasaki, Japan.
Masaki NakaiDivision of Pharmacy, Ehime University Hospital, Toon, Japan.
Takuma MatsumotoDivision of Hospital Pharmacy, NHO Shikoku Cancer Center, Matsuyama, Japan.
Yoshinobu GoharaDepartment of Pharmacy, Saga University Hospital, Saga, Japan.
Naoto HoshinoDivision of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Naoya TonomuraDivision of Hospital Pharmacy, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Manami BanbaDivision of Hospital Pharmacy, Aomori Prefectural Central Hospital, Aomori, Japan.
Ayako YamaguchiDepartment of Pharmacy, Yamagata University Hospital, Yamagata, Japan.
Masaki TachibanaDivision of Pharmacy, Nagaoka Red Cross Hospital, Nagaoka, Japan.
Tomoki FukushimaDepartment of Pharmacy, University of Yamanashi Hospital, Chuo, Japan.
Hiroki HosokawaDivision of Hospital Pharmacy, Nagaoka Chuo General Hospital, Nagaoka, Japan.
Takuya MuraDivision of Hospital Pharmacy, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Tsuyoshi YabukiDivision of Pharmacy, Uonuma Kikan Hospital, Minamiuonuma, Japan.
Shinichi WatanabeDepartment of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan.
Atsushi WatanabeDivision of Hospital Pharmacy, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Munetoshi SugiuraDepartment of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCisplatin administered at a dose of 40 mg/m PATIENTS AND

methodsThis post hoc analysis used data from a multicenter collaborative study of 961 patients with cervical cancer who received CCRT between January 2016 and March 2024. Patient characteristics and antiemetic use, including olanzapine and its dosage, were recorded. Vomiting within six days after the first cisplatin administration was evaluated. Time to vomiting onset was analyzed using Kaplan-Meier methods and multivariate Cox proportional hazards models.

resultsOlanzapine was used in 6.6% overall and 10.6% after guideline revision, indicating limited adoption. Users were younger (median age 52

conclusionOlanzapine use in patients with cervical cancer undergoing CCRT remained limited and was selectively prescribed to younger high-risk patients. No significant difference in vomiting control was observed, suggesting patient selection bias may have influenced characteristics.

Indexed as

OlanzapineUterine Cervical NeoplasmsVomitingAdultAgedAntiemeticsChemoradiotherapyCisplatinFemaleHumansIncidenceMiddle AgedAntiemeticsCisplatinOlanzapineappropriate useCCRTcervical cancercisplatinfact-finding surveyOlanzapinevomiting

Identifiers

PMID42379761
PMCPMC13322113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.